Literature DB >> 20964336

A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.

Sungwook Choi1, Derrick Sek Tong Ong, Jeffery W Kelly.   

Abstract

We describe a non-fluorescent, second generation stilbene that very selectively binds to transthyretin in complex biological environments and remains dark until it chemoselectively reacts with the pK(a)-perturbed Lys-15 ε-amino group of transthyretin to form a bright blue fluorescent conjugate. Stilbene A2 is mechanistically unusual in that it remains non-fluorescent in cell lysates lacking transthyretin, even though there is likely some proteome binding. Thus, it is especially useful for cellular imaging, as background fluorescence is undetectable until A2 reacts with transthyretin. The mechanistic basis for the effective lack of environment-sensitive fluorescence of A2 when bound to, but before reacting with, transthyretin is reported. Stilbene A2 exhibits sufficiently rapid transthyretin conjugation kinetics at 37 °C to enable pulse-chase experiments to be performed, in this case demonstrating that transthyretin is secreted from HeLa cells. As the chase compound, we employed C1, a cell-permeable, highly selective, non-covalent, transthyretin-binding dihydrostilbene that cannot become fluorescent. The progress reported is viewed as a first and necessary step toward our long-term goal of creating a one-chain, one-binding-site transthyretin tag, whose fluorescence can be regulated by adding A2 or an analogous molecule. Fusing proteins of interest to a one-chain, one-binding-site transthyretin tag regulated by A2 should be useful for studying folding, trafficking, and degradation in the cellular secretory pathway, utilizing pulse-chase experiments. Immediate applications of A2 include utilizing its conjugate fluorescence to quantify transthyretin concentration in human plasma, reflecting nutritional status, and determining the binding stoichiometry of kinetic stabilizer drugs to transthyretin in plasma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20964336      PMCID: PMC2978781          DOI: 10.1021/ja104999v

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  62 in total

1.  Blue-fluorescent antibodies.

Authors:  A Simeonov; M Matsushita; E A Juban; E H Thompson; T Z Hoffman; A E Beuscher; M J Taylor; P Wirsching; W Rettig; J K McCusker; R C Stevens; D P Millar; P G Schultz; R A Lerner; K D Janda
Journal:  Science       Date:  2000-10-13       Impact factor: 47.728

2.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.

Authors:  X Jiang; C S Smith; H M Petrassi; P Hammarström; J T White; J C Sacchettini; J W Kelly
Journal:  Biochemistry       Date:  2001-09-25       Impact factor: 3.162

3.  A fluorophore ligase for site-specific protein labeling inside living cells.

Authors:  Chayasith Uttamapinant; Katharine A White; Hemanta Baruah; Samuel Thompson; Marta Fernández-Suárez; Sujiet Puthenveetil; Alice Y Ting
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

4.  Labeling of fusion proteins with synthetic fluorophores in live cells.

Authors:  Antje Keppler; Horst Pick; Claudio Arrivoli; Horst Vogel; Kai Johnsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-28       Impact factor: 11.205

5.  Rational design of potent human transthyretin amyloid disease inhibitors.

Authors:  T Klabunde; H M Petrassi; V B Oza; P Raman; J W Kelly; J C Sacchettini
Journal:  Nat Struct Biol       Date:  2000-04

6.  Green fluorescent protein as a marker for gene expression.

Authors:  M Chalfie; Y Tu; G Euskirchen; W W Ward; D C Prasher
Journal:  Science       Date:  1994-02-11       Impact factor: 47.728

7.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.

Authors:  C C Blake; M J Geisow; S J Oatley; B Rérat; C Rérat
Journal:  J Mol Biol       Date:  1978-05-25       Impact factor: 5.469

8.  A comparative analysis of 23 structures of the amyloidogenic protein transthyretin.

Authors:  A Hörnberg; T Eneqvist; A Olofsson; E Lundgren; A E Sauer-Eriksson
Journal:  J Mol Biol       Date:  2000-09-22       Impact factor: 5.469

9.  Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.

Authors:  H E Purkey; M I Dorrell; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

10.  Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.

Authors:  Amy R Hurshman; Joleen T White; Evan T Powers; Jeffery W Kelly
Journal:  Biochemistry       Date:  2004-06-15       Impact factor: 3.162

View more
  22 in total

1.  Inhibition of curli assembly and Escherichia coli biofilm formation by the human systemic amyloid precursor transthyretin.

Authors:  Neha Jain; Jörgen Ådén; Kanna Nagamatsu; Margery L Evans; Xinyi Li; Brennan McMichael; Magdalena I Ivanova; Fredrik Almqvist; Joel N Buxbaum; Matthew R Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-30       Impact factor: 11.205

2.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

3.  Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.

Authors:  Neil P Grimster; Stephen Connelly; Aleksandra Baranczak; Jiajia Dong; Larissa B Krasnova; K Barry Sharpless; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-02-14       Impact factor: 15.419

Review 4.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 5.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

6.  Global profiling of lysine reactivity and ligandability in the human proteome.

Authors:  Stephan M Hacker; Keriann M Backus; Michael R Lazear; Stefano Forli; Bruno E Correia; Benjamin F Cravatt
Journal:  Nat Chem       Date:  2017-07-31       Impact factor: 24.427

7.  Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.

Authors:  Thomas P Smith; Ian W Windsor; Katrina T Forest; Ronald T Raines
Journal:  J Med Chem       Date:  2017-09-18       Impact factor: 7.446

8.  Second-generation covalent TMP-tag for live cell imaging.

Authors:  Zhixing Chen; Chaoran Jing; Sarah S Gallagher; Michael P Sheetz; Virginia W Cornish
Journal:  J Am Chem Soc       Date:  2012-08-09       Impact factor: 15.419

9.  A fluorogenic aryl fluorosulfate for intraorganellar transthyretin imaging in living cells and in Caenorhabditis elegans.

Authors:  Aleksandra Baranczak; Yu Liu; Stephen Connelly; Wen-Ge Han Du; Erin R Greiner; Joseph C Genereux; R Luke Wiseman; Yvonne S Eisele; Nadine C Bradbury; Jiajia Dong; Louis Noodleman; K Barry Sharpless; Ian A Wilson; Sandra E Encalada; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2015-06-08       Impact factor: 15.419

10.  Fluorogenic small molecules requiring reaction with a specific protein to create a fluorescent conjugate for biological imaging--what we know and what we need to learn.

Authors:  Aleksandra Baranczak; Stephen Connelly; Yu Liu; Sungwook Choi; Neil P Grimster; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  Biopolymers       Date:  2014-05       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.